Clinical Trial Update: Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating checkpoint inhibition with chemoradiotherapy as a bladder-sparing approach for urothelial carcinoma of the bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Urothelial Carcinoma, Bladder Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING